# Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)

> **NCT06409481** · — · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Xinxiang Medical College** · enrollment: 800000 (estimated)

## Conditions studied

- Cardiovascular Diseases
- Cardiac Diseases
- Vascular Diseases
- Cancer

## Interventions

- **DRUG:** Antineoplastic Agents

## Key facts

- **NCT ID:** NCT06409481
- **Lead sponsor:** The First Affiliated Hospital of Xinxiang Medical College
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 800000 (ESTIMATED)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06409481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06409481, "Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06409481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*